Follow
Haoda Fu
Title
Cited by
Cited by
Year
The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes
G Gaich, JY Chien, H Fu, LC Glass, MA Deeg, WL Holland, ...
Cell metabolism 18 (3), 333-340, 2013
9842013
Interpretability of cancer clinical trial results using restricted mean survival time as an alternative to the hazard ratio
K Pak, H Uno, DH Kim, L Tian, RC Kane, M Takeuchi, H Fu, B Claggett, ...
JAMA oncology 3 (12), 1692-1696, 2017
2282017
Alternatives to hazard ratios for comparing the efficacy or safety of therapies in noninferiority studies
H Uno, J Wittes, H Fu, SD Solomon, B Claggett, L Tian, T Cai, MA Pfeffer, ...
Annals of internal medicine 163 (2), 127-134, 2015
2132015
Evaluation of efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes: 12-and 24-week phase 2 studies
CM Kazda, Y Ding, RP Kelly, P Garhyan, C Shi, CN Lim, H Fu, DE Watson, ...
Diabetes Care 39 (7), 1241-1249, 2016
1822016
Short‐term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes
RP Kelly, P Garhyan, E Raddad, H Fu, CN Lim, MJ Prince, JA Pinaire, ...
Diabetes, Obesity and Metabolism 17 (4), 414-422, 2015
1082015
Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations
L Tian, H Fu, SJ Ruberg, H Uno, LJ Wei
Biometrics 74 (2), 694-702, 2018
812018
Multi-armed angle-based direct learning for estimating optimal individualized treatment rules with various outcomes
Z Qi, D Liu, H Fu, Y Liu
Journal of the American Statistical Association 115 (530), 678-691, 2020
742020
Learning optimal personalized treatment rules in consideration of benefit and risk: with an application to treating type 2 diabetes patients with insulin therapies
Y Wang, H Fu, D Zeng
Journal of the American Statistical Association 113 (521), 1-13, 2018
692018
Estimating optimal treatment regimes via subgroup identification in randomized control trials and observational studies
H Fu, J Zhou, DE Faries
Statistics in medicine 35 (19), 3285-3302, 2016
632016
Evaluating and utilizing probability of study success in clinical development
Y Wang, H Fu, P Kulkarni, C Kaiser
Clinical Trials 10 (3), 407-413, 2013
622013
Identification of subgroups with differential treatment effects for longitudinal and multiresponse variables
WY Loh, H Fu, M Man, V Champion, M Yu
Statistics in medicine 35 (26), 4837-4855, 2016
472016
Detecting outlying trials in network meta‐analysis
J Zhang, H Fu, BP Carlin
Statistics in medicine 34 (19), 2695-2707, 2015
472015
Identifying factors associated with hypoglycemia-related hospitalizations among elderly patients with T2DM in the US: a novel approach using influential variable analysis
H Fu, W Xie, B Curtis, D Schuster
Current medical research and opinion 30 (9), 1787-1793, 2014
452014
Factors associated with clopidogrel use, adherence, and persistence in patients with acute coronary syndromes undergoing percutaneous coronary intervention
B Zhu, Z Zhao, P McCollam, J Anderson, JP Bae, H Fu, M Zettler, ...
Current medical research and opinion 27 (3), 633-641, 2011
452011
Guidance on the implementation and reporting of a drug safety Bayesian network meta‐analysis
D Ohlssen, KL Price, H Amy Xia, H Hong, J Kerman, H Fu, G Quartey, ...
Pharmaceutical Statistics 13 (1), 55-70, 2014
442014
Impact of out-of-pocket pharmacy costs on branded medication adherence among patients with type 2 diabetes
WS Bibeau, H Fu, AD Taylor, AYM Kwan
Journal of managed care & specialty pharmacy 22 (11), 1338-1347, 2016
432016
Factors associated with increased healthcare costs in Medicare Advantage patients with type 2 diabetes enrolled in a large representative health insurance plan in the US
SL Slabaugh, BH Curtis, G Clore, H Fu, DP Schuster
Journal of medical economics 18 (2), 106-112, 2015
432015
Multicategory outcome weighted margin-based learning for estimating individualized treatment rules
C Zhang, J Chen, H Fu, X He, YQ Zhao, Y Liu
Statistica sinica 30, 1857, 2020
422020
Estimating individualized treatment rules for ordinal treatments
J Chen, H Fu, X He, MR Kosorok, Y Liu
Biometrics 74 (3), 924-933, 2018
412018
Closed loop control of physiological glucose
C Yamei, FU Haoda, P Garhyan, AM Haidar, RE JONES, C Kovalchick, ...
US Patent 11,901,060, 2024
372024
The system can't perform the operation now. Try again later.
Articles 1–20